The role compulsory licensing in combatting counterfeit drugs in Nigeria

The negative implication of the existence of counterfeit to the public, government and pharmaceutical companies is one of the issue examined in this study. This leads to a question of how the concept of compulsory licensing as provided for under the relevant laws can be used to address the prolifera...

Full description

Saved in:

Bibliographic Details
Main Author:	Umar, Musa Ibrahim
Format:	Thesis
Language:	eng eng
Published:	2016
Subjects:	K Law (General)
Online Access:	https://etd.uum.edu.my/6571/1/s816503_01.pdf https://etd.uum.edu.my/6571/2/s816503_02.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uum-etd.6571
record_format	uketd_dc
institution	Universiti Utara Malaysia
collection	UUM ETD
language	eng eng
advisor	Mohamed, Khadijah
topic	K Law (General)
spellingShingle	K Law (General) Umar, Musa Ibrahim The role compulsory licensing in combatting counterfeit drugs in Nigeria
description	The negative implication of the existence of counterfeit to the public, government and pharmaceutical companies is one of the issue examined in this study. This leads to a question of how the concept of compulsory licensing as provided for under the relevant laws can be used to address the proliferation of counterfeit drugs in Nigeria The objective of this study is to identify how the relevant laws on compulsory licensing can be used to address the proliferation of counterfeit drugs in Nigeria. Thus, this study employed doctrinal legal method. The content analysis is used in analyzing the data collected in this research. The study found out concept of compulsory licensing has the effect of enhancing access to affordable drugs through the authorization given to other producers to manufacture the said patented drugs and this will in turn spur competition. The study also recommends the government to issue compulsory licensing over patented drugs in order to assist the public to get of affordable and quality drugs in Nigeria
format	Thesis
qualification_name	masters
qualification_level	Master's degree
author	Umar, Musa Ibrahim
author_facet	Umar, Musa Ibrahim
author_sort	Umar, Musa Ibrahim
title	The role compulsory licensing in combatting counterfeit drugs in Nigeria
title_short	The role compulsory licensing in combatting counterfeit drugs in Nigeria
title_full	The role compulsory licensing in combatting counterfeit drugs in Nigeria
title_fullStr	The role compulsory licensing in combatting counterfeit drugs in Nigeria
title_full_unstemmed	The role compulsory licensing in combatting counterfeit drugs in Nigeria
title_sort	role compulsory licensing in combatting counterfeit drugs in nigeria
granting_institution	Universiti Utara Malaysia
granting_department	Ghazali Shafie Graduate School of Government
publishDate	2016
url	https://etd.uum.edu.my/6571/1/s816503_01.pdf https://etd.uum.edu.my/6571/2/s816503_02.pdf
_version_	1747828095055822848
spelling	my-uum-etd.65712021-12-08T03:25:44Z The role compulsory licensing in combatting counterfeit drugs in Nigeria 2016 Umar, Musa Ibrahim Mohamed, Khadijah Ghazali Shafie Graduate School of Government Ghazali Shafie Graduate School of Government K Law (General) The negative implication of the existence of counterfeit to the public, government and pharmaceutical companies is one of the issue examined in this study. This leads to a question of how the concept of compulsory licensing as provided for under the relevant laws can be used to address the proliferation of counterfeit drugs in Nigeria The objective of this study is to identify how the relevant laws on compulsory licensing can be used to address the proliferation of counterfeit drugs in Nigeria. Thus, this study employed doctrinal legal method. The content analysis is used in analyzing the data collected in this research. The study found out concept of compulsory licensing has the effect of enhancing access to affordable drugs through the authorization given to other producers to manufacture the said patented drugs and this will in turn spur competition. The study also recommends the government to issue compulsory licensing over patented drugs in order to assist the public to get of affordable and quality drugs in Nigeria 2016 Thesis https://etd.uum.edu.my/6571/ https://etd.uum.edu.my/6571/1/s816503_01.pdf text eng public https://etd.uum.edu.my/6571/2/s816503_02.pdf text eng public masters masters Universiti Utara Malaysia A Serious Threat to Patient Safety Counterfeit Pharmaceuticals,:8, http://www.pfizer.com/files/products/CounterfeitBrochure.pdf (accessed March 8, 2015). Abimbola Kolawole Omolara Dahunsi,“Patent rights and essential medicines in developing countries: is access compromised for innovation in Nigeria?,” Journal of Medicine and Medical Sciences 3 no.3 (March 2012):132, http://www.interesjournals.org/JMMS (accessed February 9, 2015). Abdulganiyu Giwa and Tayo Fola, “Poverty, Affordability of Anti-Diabetic Drugs and Glycemic Control: An Unholy Alliance in a Developing Economy ?,” International Journal of Pharma Sciences and Research 5(September 2013):114, http://www.ijpsr.info/docs/IJPSR13-04-09-002.pdf (accessed January 9, 2015). Agbaraji Emmanuel C., Deborah O. Ochulor and Gloria N. Ezeh, “Food And Drug Counterfeiting in the Developing Nations; the Implications and Way-Out,” Academic Research International 3 no.2 (September 2012):24, http://paper.researchbib.com/?action=viewList&issn=22239944&vol=3&no=2. (accessed February 8, 2015). Akande Tanimola Makanjuola,“Population With Ill-Health Burden; Faced With A Sick Health System,” (2014):24, https://www.unilorin.edu.ng/UIL/142.pdf (accessed January 8, 2015). Akinyademu Olusegun, “Counterfeit Drugs in Nigeria: A Threat to Public Health,” African Journal of Pharmacy and Pharmacology 7 no. 36 (September 2013):2574, www.academicjournals.org/article/article1381822397_Akinyandenu.pdf (accessed February 23, 2015). Akunyili Dora, “Fake and Counterfeit Drugs in the Health Sector: The Role of Medical Doctors,” Annals of Ibadan Postgraduate Medicine 2 no .2 (December,2004):20, http://www.ajol.info/index.php/aipm/article/viewFile/39094/26216. (accessed February 5, 2015). Akunyili Dora, “Counterfeit and Substandard Drugs, Nigeria’s Experience: Implications, Challenges, Actions and Recommendations”(March 2005):11, http://siteresources.worldbank.org/INTAFRREGTOPHIVAIDS/Resources/717089-1113520923653/Dora_Akunyili-Good_Intentions-Bad_Drugs-MAR_10_05.doc. (accessed March 14, 2015). Akunyili D. N., “Consideration of Intellectual Property Rights in Regulation and Control: Activities of the National Agency For Food And Drug Administration And Control (Nafdac),” (May 15 -17,2006): 3-8, Http://Www.Wipo.Int/Edocs/Mdocs/Enforcement/En/Wipo_Ace_3/Wipo_Ace_3_9.Doc. (accessed February 21,2015). Akunyili D. N., “Is the Time Ripe for an International Anticounterfeiting Commission?,”:17, http://projects.msh.org/seam/conference2005/pdf/Day1/37_Tr03_Akunyili_speech.pdf (accessed March 5, 2015). Akunyili Dora N., “Counterfeit Drugs and Pharmacovigilance,” (May 2005):28 - 43, http://www.fug.se/ovrigt/Akunyili.pdf (accessed February 11, 2015). Akunyili Dora, “Lessons from Nigeria: the fight against counterfeit drugs in Africa,”: 2, http://apps.who.int/medicinedocs/documents/s18404en/s18404en.pdf. (accessed January 30, 2015). Akunyili Dora Nkem, “Women Leadership in Emerging Democracy – My Nafdac Experience” (April 2006):9, www.wilsoncenter.org/sites/default/files/akunyili_speech.pdf (accessed March 15, 2015). Aniebue Patricia Nonye, Emmanuel Nwabueze Aguwa and Emmanuel Ikechukwu Obi, “Universal Precautions: Awareness and Practice of Patent Medicines Vendors in Enugu Metropolis, South East Nigeria,” Nigerian Medical Journal (2010):30, .nigeriamedj.com/temp/NigerMedJ51130-7587251_210432.pdf (accessed March 7, 2015). Awosusi Abiodun , “Nigeria on the Move towards Universal Health Coverage,” https://www.msh.org/blog/2013/07/22/nigeria-on-the-move-towards-universal-health-coverage (accessed April 27, 2015). Auta Asa, Simeon Omale, Nwamaka C. Anukam and Kennedy I. Amagon, “Patent Medicine Vendors’ Clients: Medicine Use Behaviour,” journalmanagers.org/files/journals/1/articles/23/.../23-69-1-RV.docx (accessed March 7, 2015). Baker Brook K., “Patents, Pricing, and Access to Essential Medicines in Developing Countries,” American Medical Association Journal of Ethics Volume 11, Number 7 (July 2009):528, http://journalofethics.ama-assn.org/2009/07/pfor1-0907.html (accessed March 26, 2015). Bah-Traore Ndjamawe,“Quality Assurance and Safety issue of Pharmaceutical Products marketed in Developing countries,” (2012):52, http://hss.ulb.uni-bonn.de/2012/3056/3056.pdf (accessed March 4, 2015). Bansal Dipika, Swathi Malla, Kapil Gudala and Pramil Tiwari, “Anti-Counterfeit Technologies: A Pharmaceutical Industry Perspective,” Scientia Pharmaceutica ( 2013):2, http://www.scipharm.at/default.asp?id=1301&lid=2 (accessed March 15,2015). Bello A. Chika, S.O, A.O Jimoh and M.T Umar, “The Menace of Fake Drugs:Consequences, Causes and Posssible Solutions,” Research Journal of Medical Sciences 5 (2011):258, http://docsdrive.com/pdfs/medwelljournals/rjmsci/2011/257-261.pdf (accessed March 10, 2015). Benoliel Daniel and Timothy John Chirwa,“The Impact of Pharmaceutical Patents on Health E.xpenditures in Least-Developed Countries,”:3, http://weblaw.haifa.ac.il/he/Faculty/BenOliel/Publications/BenolielChirwa.pdf. (accessed March 19, 2015). Bessen James and Eric Maskin,“Sequential innovation, patents, and imitation,” Rand Journal of Economics Vol. 40, No. 4 (Winter 2009):611, scholar.harvard.edu/.../sequential_innovation_patents_and_imitation.pdf (accessed March 25, 2015). Biadgleng Ermias Tekeste, “Trips Post-Grant Flexibilities: Parallel Imports Workshop on Flexibilities in International Intellectual Property Rules and Local Production of Pharmaceuticals for the Southern, Central and West African Region (December 2009):3, unctad.org/sections/dite_totip/docs/tot_ip_0022_en.pdf (accessed April 7, 2015). Black's Law Free Online Legal Dictionary 2nd Ed. [http://thelawdictionary.org/adulteration/.(accessed Janaury28, 201). Bondy Eric and Kamal Saggiz, “Compulsory licensing, price controls, and access to patented foreign products,” (April 2012):4, http://www.wipo.int/edocs/mdocs/mdocs/en/wipo_ip_econ_ge_4_12/wipo_ip_econ_ge_4_12_ref_saggi.pdf (accessed March 12, 2015). Burci Gian Luca, “Public Health and “Counterfeit” Medicines: The Role of the World Health Organization,” http://www.asil.org/insights/volume/17/issue/2/public-health-and-%E2%80%9Ccounterfeit%E2%80%9D-medicines-role-world-health-organization ((accessed February 5, 2015). C.H. Ugwuishiwu, Inyiama H.C. and Ezema M.E, “A Model of NAFDAC Real-Time Crime Information System,” International Journal of Soft Computing and Engineering 2 no.5 (November 2012):1, http://www.ijsce.org/attachments/File/v2i5/E0967092512.pdf. (accessed January 22,2015). “Championing the Fight against Fake Drugs,” http://www.wipo.int/portal/en/news/2008/article_0012.html (accessed February 22, 2015). Chika A. ,S.O. Bello,A.O. Jimoh and M.T. Umar, “The Menace of Fake Drugs: Consequences, Causes and Possible Solutions,” Research Journal of Medical Sciences 5 no. 5(2011):257, http://www.medwelljournals.com/abstract/?doi=rjmsci.2011.257.261(accessed February 2, 2015). Chien Colleen, “Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation,” Berkeley Technology Law Journal Volume 18 Issue 3 (June 2003): 855, www.btlj.org/data/articles/vol18/Chien.web.pdf (accessed March 26, 2015). Chinwendu Olike, The fight against fake drugs by NAFDAC in Nigeria (September 2008):3, http://www.medbox.org/pharmacy-technologies/the-fight-against-fake-drugs-by-nafdac-in-nigeria/preview?q= (accessed May 6, 2015). Choi Hye Lynn, David Lee and Jude Nwokike, “Safety of Medicines in Sub-Saharan Africa Assessment of Pharmacovigilance Systems and their Performance,” : 23, apps.who.int/medicinedocs/documents/s19152en/s19152en.pdf (accessed February 5,2015). Chukindi Joe , “Nigeria Cannot Attain Mdgs with Fake Drugs in Circulation – Nafdac,”(1stMarch,2014 ) http://dailypost.ng/2014/03/01/nigeria-attain-mdgs-fake-drugs-circulation-nafdac/ (accessed February 22, 2015). Chukwuemeka Emma and Christian Okafor, “Obstacles to Malaria Control Policy in Nigeria: an Assessment of the Impact of Counterfeit Drugs and Regulatory Policies,” Kuwait Chapter of Arabian Journal of Business and Management Review 1 no. 1 (September 2011):121. http://omicsonline.com/open-access/2224-8358/2224-8358-1-108.pdf?aid=17060 ( Accessed on January 7,2015). “Compulsory Licensing and the Anti-Competitive Effects of Patents for Pharmaceutical Products: from a Developing Countries’ Perspective,”(October 2009):1, http://www.cuts-citee.org/pdf/Compulsory_Licenses_and_anti-competitive_effects_of_patents.pdf.(accessed April 4, 2015). Cockburn Robert, Paul N. Newton, E. Kyeremateng Agyarko, Dora Akunyili and Nicholas J. White, “The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers,”Plos Med 2(4)(2005), http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pmed.0020100&representation=PDF (accessed March 17, 2015). Correa Carlos, “Integrating Public Health Concerns into Patent Litigation in Developing Countries,”: 93, www.who.int/medicinedocs/pdf/h2963e/h2963e.pdf (accessed March 28, 2015). Dambazau Abdulrahman, “Overcoming Nigeria’s Security Challenges,”:10, http://www.iuokada.edu.ng/Files/Convocation/Overcoming%20Nigerias%20Security%20Challenges.pdf. (accessed March 7, 2015). Dike Onwubiko N, Julius O. Onah, and Emmanuel Onwuka,“An Assessment of the Effects of Communication Network in Curbing Unethical Marketing Practices of Drug Firms in Nigeria,” Management and Administrative Sciences Review Vol 3. Issue 2 (March 2014):3, http://absronline.org/journals/index.php/masr/article/viewFile/175/196(accessed February 6, 2015). Dodoo Alex, “Patient Safety Problems Related to Drug Counterfeiting,” pg 6, https://www.google.com.my/search?q=Alex+Dodoo%2C+%E2%80%9CPatient+Safety+Problems+Related+to+Drug+Counterfeiting%2C%E2%80%9D&oq=Alex+Dodoo%2C+%E2%80%9CPatient+Safety+Problems+Related+to+Drug+Counterfeiting%2C%E2%80%9D&aqs=chrome..69i57.433j0j4&sourceid=chrome&es_sm=93&ie=UTF-8 (accessed February 5, 2015). Dogarawa Lawal Bello, “Overview of the Socioeconomic Implications and Management of Product Faking and Adulteration,” Greener Journal of Business and Management Studies 3 no.3 (April 2013):124, http://www.gjournals.org/GJMBS/PDF/2013/April/Dogarawa.pdf. (accessed February 11, 2015). “Don alerts FG on prevalence of fake drugs in Nigeria,” http://www.vanguardngr.com/2014/02/don-alerts-fg-prevalence-fake-drugs-nigeria/#sthash.HojZV7Mj.dpuf (accessed March 12, 2015). Drug Counterfeit – A Global Menace and its Remedial Measures, http://www.pharmainfo.net/reviews/drug-counterfeit-global-menace-and-its-remedial-measures (accessed March 5, 2015). Elliott Richard and Marie-Hélène Bonin, “Patents, International Trade Law and Access to Essential Medicines,”:3, http://www.umich.edu/~spp638/Coursepack/ipr-msf.pdf. (accessed March 19, 2015). Ezejiofor Gaius, “The law of Patents in Nigeria: A Review,”:50, http://heinonline.org/HOL/LandingPage?handle=hein.journals/jlpul9&div=5&id=&page= (accessed February 22, 2015). Fenoff Roy S. and Jeremy M. Wilson, “Africa’s Counterfeit Pharmaceutical Epidemic: The Road Ahead,” (October 2009):5, http://a-capp.msu.edu/sites/default/files/files/AfricaPharmaPaperFINAL.pdf.(accessed February 12, 2015). “Fields of Intellectual Property Protection,” https://www.google.com/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF8#q=a+document%2C+issued%2C+upon+application%2C+by+a+government+office+(or+a+regional+office+acting+for+several+countries)%2C+which+describes+an+invention+and+creates+a+legal+situation+in+which+the+patented+invention+can+normally+only+be+exploited+(manufactured%2C+used%2C+sold%2C+imported)with+the+authorization+of+the+owner+of+the+patent (accessed May 6, 2015). “Frequently asked questions about TRIPS [trade-related aspects of intellectual property rights] in the WTO,” https://www.wto.org/english/Tratop_e/trips_e/tripfq_e.htm (accessed February 28, 2015). Grabowski Henry, “Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act,”: 462, https://fds.duke.edu/db/attachment/326 (accessed March 19, 2015). Garuba Habibat A, Jillian C Kohler and Anna M Huisman, “Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers,” Globalization and Health 5 (2009):9, http://www.globalizationandhealth.com/content/5/1/14 (accessed March 4, 2015). Gibson Christopher, “A Look at the Compulsory License in Investment Arbitration: The Case of Indirect Expropriation,” American University International Law Review Vol. 25 Issue 3 (2010):362, digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?article=1072 (accessed March 28, 2015). G Bakthavathsalam, “Generic Drugs: Cost Effective Alternate To Branded Drugs,” Health Administrator Vol : XIX Number 1:17, medind.nic.in/haa/t06/i1/haat07i1p16.pdf (accessed April 8, 2015). Gustafsson-Wright Emily And Onno Schellekens,” Achieving Universal Health Coverage In Nigeria One State At a Time,” (june 2013):8, http://www.brookings.edu/~/media/research/files/papers/2013/06/achieving-universal-health-coverage-nigeria-gustafsson-wright/achieving-universal-health-coverage-in-nigeria.pdf. (accessed april 27, 2015). Gupta Raadhika, “Compulsory Licensing under Trips: How far it Addresses Public Health Concerns in Developing Nations ,” Journal of Intellectual Property Rights Vol. 15 (September 2010):358, nopr.niscair.res.in/bitstream/123456789/.../JIPR%2015(5)%20357-363.pdf (accessed May 12, 2015). Harris Julian, Helmy Haja Mydin, Philips Stevens and Julian Morris, “Keeping it Real Combating Fake Drugs in Malaysia November 2011,”:8, http://ideas.org.my/wp-content/uploads/2011/11/Fake-Drugs-Nov-20111.pdf (accessed March 10, 2015). Hestermeyer Holger P., “Access to Medicines 2.0: Preferential Trade Agreements as an Impediment to Access,”:1, https://www.academia.edu/1194914/Access_to_Medicines_2.0_Preferential_Trade_Agreements_as_an_Impediment_to_Access (accessed February 9,2015). Hoen Ellen F. M.’t, “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond,”(2003):42, http://www.who.int/intellectualproperty/topics/ip/tHoen.pdf. (accessed February 27, 2015). Ho Cynthia M., “Compulsory Licenses Under Trips: An Introduction,”: 130- 131, http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1922803 (accessed April 4, 2015). http://www.gamji.com/article8000/NEWS8815.htm (accessed March 6, 2015). http://www.who.int/trade/glossary/story076/en/ (accessed February 6, 2015). http://www.medicinenet.com/script/main/art.asp?articlekey=3120 (accessed February 6, 2015). http://www.who.int/features/qa/75/en/ (accessed February 6, 2015). http://www.who.int/features/qa/75/en/ (accessed February 6, 2015). http://www.scielo.org.za/pdf/ahrlj/v13n2/10.pdf ( accessed January 6, 2015). http://www.chr.up.ac.za/undp/other/docs/policy2.pdf ( accessed on January 7, 2015). http://www.cenbank.org/rates/ExchRateByCurrency.asp?CurrencyType=$USD (accessed February 22, 2015). Islam Mohammad Towhidul, Trips Agreement of the WTO: Implications and Challenges for Bangladesh: 164, https://books.google.com.my/books?id=3tsxBwAAQBAJ&pg=PA164&lpg=PA164&dq=what+is++early+working+%28bolar+provision%29&source=bl&ots=VLdiSIaBZa&sig=lsFA0v4XFbR9JV9XHoBCqDS9mk&hl=en&sa=X&ei=YPcjVammB8SjugSMroCwBw&ved=0CDsQ6AEwBTgK#v=onepage&q=what%20is%20%20early%20working%20(bolar%20provision)&f=false (accessed April 8, 2015). Inside WIPO, http://www.wipo.int/about-wipo/en/ (accessed May 6, 2015). Intellectual Property Office of Singapore, “What is a Patent,” http://www.ipos.gov.sg/AboutIP/TypesofIPWhatisIntellectualProperty/Whatisapatent.aspx (accessed May 10, 2015). Iwokwagh Nicholas S., “Assessment of New Media use in the Fight against Counterfeit Medicines in Nigeria,” (May, 2013): 20, http://www.cmdconf.net/2013/makale/PDF/5.pdf (accessed January 8, 2015). Iyanda Ayobola Abolape, “A Study On The Impact Of Fake Paracetamol Syrup On Serum Micronutrient Levels In Female Wistar Rats,” World Journal of Pharmacy and Pharmaceutical Sciences 3 no. 7(2014):123, http://www.wjpps.com/download/article/1404458960.pdf (accessed February 8, 2015). JDSU, “Pharmaceutical Counterfeiting, Tampering, and Diversion: Solutions for Addressing a Growing Threat,”:4, http://www.jdsu.com/ProductLiterature/Pharmaceutical_White_Paper.pdf. (accessed March 11, 2015). Karlsson Anders, “Green technology patents. - TRIPS, compulsory licensing and global health,” (2014):10, www.diva-portal.org/smash/get/diva2:764784/fulltext01.pdf (accessed April 4, 2015). Kashyap Amit K and Anjani Singh Tomar, “Trips & Public Health: With Special Reference to Doha Declaration & Indian Patents Law” International Journal of Health Sciences Vol. 1 No. 1 (December 2013): 4, http://ijhsnet.com/journals/ijhs/Vol_1_No_1_December_2013/1.pdf (accessed April 6, 2015). Keshi Chuba ,”In-Licensing as a Business Strategy for Pharmaceutical Companies: A Framework for the Nigerian Industry,” (May 2012):3, http://c807089.r89.cf2.rackcdn.com/KESHI-Chuba-Doctoral-Proposal-Final.pdf. (accessed March 5, 2015). Kennedy Leslie W. and Edmund F. McGarrell, ed., “Crime and Terrorism Risk: Studies in Criminology and Criminal Justice,” https://books.google.com.my/books?id=tHSQAgAAQBAJ&pg=PT377&lpg=PT377&dq=70+percent+of+the+drugs+sold+in+Nigeria+WHO,+2008;+PrimoCarpenter,+2009%29&source=bl&ots=Q8BMf3DFcT&sig=w2nrLdOlgIHA704beBAcNkMIOdA&hl=en&sa=X&ei=R0XaVNvAs6fugSulYEY&ved=0CCMQ6AEwAQ#v=onepage&q&f=false (accessed February 12, 2015). Ladan Muhammed Tawfiq, “The Limits of Legal and Enforcement/Regulatory Frameworks in Consumer Protection Against Counterfeit and Pirated Products: - The Nigerian Experience,” Review of Nigerian Law and Practice 2 no.1(2008):25, http://www.unisza.edu.my/library/images/IDC/counterfeit.pdf (accessed January 21, 2015). Lehman Bruce, “The Pharmaceutical Industry and the Patent System,”:7, users.wfu.edu/mcfallta/DIR0/pharma_patents.pdf (accessed March 25,2015). Ling Chee Yoke, “Malaysia’s Experience in Increasing Access to Antiretroviral Drugs: Exercising the ‘Government Use’ Option,”(2006):14, https://www.citizen.org/documents/MalaysianCLexperienceIPRSeries%20No%209.pdf (accessed May 11, 2015). Machlup Fritz and Edith Penrose, “The Patent Controversy in the Nineteenth Century,” The Journal of Economic History Vol. 10 No.1 (May 1950):10 and 13, http://c4sif.org/wp-content/uploads/2010/09/Machlup-Penrose-The-Patent-Controversy-in-the-Nineteenth-Century-1950-b.pdf. (accessed March 24, 2015). Matthews Duncan, “WTO Decision on Implementation of Paragraph 6 of the Doha Declaration on the Trips Agreement and Public Health: A Solution to the Access to Essential Medicines Problem?,” Journal of International Economic Law 7(1) (march 2004):2. http://jiel.oxfordjournals.org/content/7/1/73.full.pdf+html (accessed March 26, 2015). Maybarduk Peter, “Compulsory Licensing and its lessons for the A2M movement,” (October 2008):10, https://uaem.org/cms/assets/uploads/2013/03/uaemconference2008-compulsory-licensing.ppt. (accessed March 1, 2015). “Member Information Nigeria and the WTO,” https://www.wto.org/english/thewto_e/countries_e/nigeria_e.htm (accessed February 28, 2015). Mukhtar Nasiru, “Nature and Scope of Intellectual Property Law: An Appraisal of Concepts, Issues and Prospects for Developing Economies,” Journal of Politics and Law Vol. 6, No. 2 (2013):205, http://ccsenet.org/journal/index.php/jpl/article/view/27872/16825 (accessed May 10, 2015). Module V Patents:3, https://www.wto.org/english/tratop_e/trips_e/ta_docs_e/modules5_e.pdf (accessed June 1, 2015). Mohammed Shaba, “Practical Tools and Approaches for SPOCS - Nigerian Experience,” (January 2015):18, http://www.nifds.go.kr/apec/files/tp201501/(30)%20Shaba%20-%20SPOCs%20Nigeria%20-%2029jan2015.pdf. (accessed April 8, 2015). Musungu Sisule .F., “The Use of Flexibilities in Trips by Developing Countries: Can they promote access to Medicine?,”(August 2005):vi, www.who.int/intellectualproperty/studies/tripsflexi.pdf (accessed April 7, 2015). Muthiani Muli, “ Factors Influencing the Influx of Counterfeit Medicines in Kenya: A Survey of Pharmaceutical Importing Small and Medium Enterprises within Nairobi,” International Journal of Business and Social Science Vol. 3 No. 11 (June 2012):4, http://ijbssnet.com/journals/Vol_3_No_11_June_2012/10.pdf (accessed March 17, 2015). “NAFDAC Destroys N482.2m Fake Drugs in Awka,” Thisday Live, February 21, 2015. http://www.thisdaylive.com/articles/nafdac-destroys-n482-2m-fake-drugs-in-awka/202315/ (accessed February 22, 2015). NAFDAC “Nafdac and Kano State Government Jointly Destroys N600m Fake Drugs,” November 30, 2013, http://www.nafdac.gov.ng/component/k2/item/230-nafdac-and-kano-state-government-jointly-destroys-n600m-fake-drugs (accessed February 22, 2015). NAN, “Sub-Standard Drugs Threat To MDG’s Goals, Says NAFDAC,” Leadership Nigeria, February 28, 2014, http://leadership.ng/news/350472/sub-standard-drugs-threat-mdgs-goals-says-nafdac (accessed February 12, 2015). Nnabuihe Nwachukwu Sunny, Nwachukwu Tobechukwu Odunze and Nwosu Ezekwesiri Okebugwu, “World Trade Organization and the Developing World Nigerian Economy: A Case Study,” European Scientific Journal 1(September 2014): 395, http://eujournal.org/index.php/esj/article/download/4109/3942. (accessed March 19, 2015). Nwabuisi Charles, “Antimicrobials and Superbugs: The Survival Game,” (November, 2014):28, https://www.unilorin.edu.ng/UIL/154.pdf (accessed February 6, 2015). Nwobike C., “Pharmaceutical Corporations and Access to Drugs in developing Countries: the Way Forward,” International Journal On Human Rights Number 4(2006):127, www.surjournal.org/eng/conteudos/artigos4/ing/artigo_nwobike.htm (accessed March 26, 2015). O. Alan Sykes, “TRIPs, Pharmaceuticals, Developing Countries and the Doha Solution,”: 2, http://papers.ssrn.com/abstract=300834 (accessed March 26, 2015). Obi Nnamdi, “War against fake drugs is like fighting Boko Haram," http://sunnewsonline.com/new/?p=61224 (accessed March 7, 2015). Obinna Chioma and Gabriel Olawale, “NAFDAC introduces new anti counterfeiting technologies,”(June 12, 2010). http://www.vanguardngr.com/2010/06/nafdac-introduces-new-anti-counterfeiting-technologies/#sthash.IOZvUOso.dpuf (accessed March 15, 2015). Obinna Chioma, Kosiso Udemba & Modinat Amusat,” FG bans sale of drugs in open market,” (August 21, 2013), .http://www.vanguardngr.com/2013/08/fg-bans-sale-of-drugs-in-open-market/ (accessed March 12, 2015). Odunsi S. Babafemi, “Pharmaceutical Industry, Patenting, Human Rights and Access to Treatment in Developing Countries; Another look at Commercialization of Bio- Medical Research,” https://www.google.com.my/search?q=S.+Babafemi+Odunsi%2C+%E2%80%9CPharmaceutical+Industry%2C+Patenting%2CHuman+Rights+and+Access+to+Treatment+in+Developing+Countries%3B+Another+look+at+Commercialization+of+Bio+Medical+Research%2C%E2%80%9D&oq=S.+Babafemi+Odunsi%2C+%E2%80%9CPharmaceutical+Industry%2C+Patenting%2CHuman+Rights+and+Access+to+Treatment+in+Developing+Countries%3B+Another+look+at+Commercialization+of+Bio+Medical+Research%2C%E2%80%9D&aqs=chrome..69i57.1687j0j4&sourceid=chrome&es_sm=93&ie=UTF8#q=S.+Babafemi+Odunsi%2C+Pharmaceutical+Industry%2C+Patenting%2CHuman+Rights+and+Access+to+Treatment+in+Developing+Countries%3B+Another+look+at+Commercialization+of+Bio-+Medical+Research. (accessed February 22, 2015). Office of Health Economics, “OHE Study on Pharmaceutical R&D Costs Released,” (December 3, 2012), https://www.ohe.org/news/ohe-study-pharmaceutical-rd costs-released (accessed February 9, 2015). Ogundipe Sola,”Nigerians pay for cancer treatment with their lives,” (September 22, 2013), http://www.vanguardngr.com/2013/09/nigerians-pay-for-cancer-treatment-with-their-lives/ (accessed April 8, 2015). Ojo Solomon αnd Adeyemi Oluwakemi OJO, “Prevalence of Counterfeiting in Nigeria: Evaluating Consumers’ Experience in South Eastern and South-Western Nigeria,” Global Journal of Human Social Science Sociology, Economics & Political Science Vol.12 Iss. 12 (2012):87, https://globaljournals.org/GJHSS_Volume12/7-Prevalence-of-Counterfeiting-in-Nigeria.pdf (accessed May 11, 2015). Olayemi Adebayo Oyefunke, “Analysis Of Poverty Level Among Urban Households In Irewole Local Government Area Of Osun State,” Global Journal of Arts Humanities and Social Sciences, 1 No.1(March 2013):13, http://www.eajournals.org/wp-content/uploads/gjahsanalysis-of-poverty-level amongurbanhouseholds.pdf. (accessed February 27, 2015). Olugbenga Olatunji , E., “Impact of Administrative Law on the Functioning of Regulatory Agencies: Cases and Materials from a Third World Country,” International Research Journal of Law 1 no. 1 ( March 2014):7, http://acascipub.com/Journals.php (accessed February 24, 2015). Olugbenga Olugbenga, Ebenezer, “The Politics and Pathology of Drug Service Administration in Third World Countries: Lessons of Two Drug Distribution Experiments in Nigeria,” Research on Humanities and Social Sciences 4 no. 8 (2014):1,http://www.iiste.org/Journals/index.php/RHSS/article/view/12472.(accessed January20, 2015). Olugbenga Ebenezer Olatunji “The Politics of Pharmaceutical Regulation in Nigeria: Policy Options for Third World Countries,” Public Policy and Administration Research Vol.3, No.8 (2013):92, http://www.iiste.org/Journals/index.php/PPAR/article/view/7105/7338(accessed March 4, 2015). Olayiwola Saheed O. and Olanrewaju A. Olaniyan, “The Welfare Effects of Health Insurance in Nigeria,” https://editorialexpress.com/cgibin/conference/download.cgi?db_name=CSAE2014&paper_id=345.https://editorialexpress.com/cgibin/conference/download.cgi?db_name=CSAE2014&paper_id=345(accessed February 27, 2015). Olatunji Olugbenga Ebenezer, “The Politics and Pathology of Drug Service Administration in Third World Countries: Lessons of Two Drug Distribution Experiments in Nigeria,” Research on Humanities and Social Sciences 4 no. 8 (2014):1, http://www.iiste.org/Journals/index.php/RHSS/article/view/12472. ( accessed January7, 2015). Olugbenga Olatunji , E., “Impact of Administrative Law on the Functioning of Regulatory Agencies: Cases and Materials from a Third World Country,” International Research Journal of Law 1 no. 1 ( March 2014):7, http://acascipub.com/Journals.php (accessed January 24, 2015). Omojokun Jane, “Regulation and Enforcement of Legislation on Food Safety in Nigeria,” (2013):254. http://www.intechopen.com/download/pdf/44083. (accessed January 25, 2015). Onwuka Chioma Joy, “The Situation of Medicines counterfeiting in Africa,”(2010):20, http://www.whpa.org/background_medicines_counterfeiting_in_aTjhfrica_chioma_jo_onwuka11-2010.pdf.(accessed February 6, 2015). Ong Burton, “Compulsory Licences of Pharmaceutical Patents to Remedy Anti-Competitive Practices Under Article 31(k) of the TRIPS Agreement: Can Competition Law Facilitate Access to Essential Medicines?,” :236, http://bookzz.org/book/2473945/c288dd (accessed March 26, 2015). Onwuka Chioma Joy, “The Situation of Medicines counterfeiting in Africa,”(2010):20, http://www.whpa.org/background_medicines_counterfeiting_in_aTjhfrica_chioma_jo_onwuka11-2010.pdf.(accessed February 6, 2015). “Open Market”, http://www.investopedia.com/terms/o/open-market.asp (accessed March 4, 2015). Patentability under the Nigerian Patents and Designs Act (PDA): An Introductory Analysis, http://www.templarslaw.com/media/Patentability%20Under%20the%20Nigerian%20Patent%20Act.pdf. (accessed March 1, 2015). PHRMA, “2013 profile Biopharmaceutical Research Industry,” (2013): 32, http://www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf (accessed March 19, 2015). Phillips Kaye, “Compulsory Licensing in Thailand: A Case Study,” (October 2008):20 and 25, https://uaem.org/cms/assets/uploads/2013/03/uaemconference2008-compulsory-licensing.ppt.(accessed March 1, 2015). Perkins Lawrence, “Commentary Pharmaceutical companies must make decisions based on profit,” West J Med 175 (December 2001):422, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1275981/ (accessed May 9, 2015). Ratanawijitrasin Sauwakon and Eshetu Wondemagegnehu, “Effective drug regulation A multicountry study,” (2002):7, www.who.int/medicinedocs/pdf/s2300e/s2300e.pdf (accessed February 4,2015). Sandhya HV, “General Principles Of Patent Law” (2014):58, shodhganga.inflibnet.ac.in/bitstream/10603/21666/4/chapter-iii.pdf (accessed June 1, 2015). Shadlen Kenneth, “Patents and Pills, Power and Procedure: The North-South Politics of Public Health in the WTO,” No. 03-42 (2003):20, www.lse.ac.uk/internationalDevelopment/pdf/WP/WP42.pdf (accessed March 27, 2015). Stavropoulou Charitini and Tommaso Valletti, “Compulsory licensing and access to drugs,” Eur J Health Econ(Decemeber2013):2, http://www.cresse.info/uploadfiles/Compulsory%20licensing%20and%20access%20to%20drugs.pdf.(accessed May 12, 2015). Sulander Jaakko, ” The Role of Compulsory Licensing in Improving Access to Essential Medicines in Developing Countries,” (2001/ 2002) :5,https://www.kent.ac.uk/law/ip/resources/ip_dissertations/2001-02/Diss-Sulander.doc (accessed May 8, 2015). Taylor Nick, “Nafdac Launches Mobile Anti- Counterfeiting Service,”(February3, 2010), http://www.inpharmatechnologist.com/Drug-Delivery/NAFDAC-launches-mobile-anti-counterfeiting service?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright (accessed March 15, 2015). T.G “Trips Agreement and Public Health: The Post Doha Crisis,”Journal of Intellectual Property Rights Vol 18(May 2013):289, nopr.niscair.res.in/bitstream/123456789/.../JIPR%2018(3)%20287-293.pdf (accessed April 6, 2015). The Nigerian National Bureau of Statistics (NBS), “The Nigeria Poverty Profile 2010 Report,” (February 13, 2105):8, http://reliefweb.int/sites/reliefweb.int/files/resources/b410c26c2921c18a6839baebc9b1428fa98fa36a.pdf(accessed May 10, 2015). The American Consumer Institute Center for Citizen Research, “Lifesaving Drugs at Lower Costs,”:1, www.theamericanconsumer.org/.../Biosimilars-ConsumerGram-Final.pdf (accessed April 8, 2015). “Trips and Health: Frequently Asked Questions Compulsory Licensing of Pharmaceuticals and Trips,” https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm (accessed March 28, 2015). “TRIPS: A More Detailed Overview of the Trips Agreement Overview: the TRIPS Agreement,” https://www.wto.org/English/tratop_e/TRIPS_e/intel2_e.htm (accessed February 28, 2015). Udo Bassey , “40 per cent of goods in Nigeria are substandard, counterfeit – SON,” Premium Times, August 11, 2014, http://www.premiumtimesng.com/opinion/166460-interview-40-per-cent-of-goods-in-nigeria-are-substandard-counterfeit-son.html (accessed May 11, 2015). Umahi Okechukwu Timothy, “Access to Medicines: the Colonial Impacts on Patent law of Nigeria,”:17, http://www.nlipw.com/wp-content/uploads/Access-to-Medicines-the-Colonial-Impact-on-Patent-Law-of-Nigeria-by-Timothy-Umahi.pdf . (accessed February 26, 2015). Umahi Okechukwu Timothy, “Proactive Legal Reforms through Nigerian Universities and Nigerian Bar Association push: A case for Intellectual Property Commission (NIPCOM) Bill,” Journal of Jurisprudence and Contemporary Issues 6 no.2 (2012); 4. Umeha Chioma , “Our porous borders are entry points for fake, spurious products,”(March 6, 2014) http://www.mydailynewswatchng.com/porous-borders-entry-points-fake-spurious-products-obi/ (accessed Janaury 12, 2015). Waziri K.M, Intellectual Property Piracy and Counterfeiting in Nigeria: The Impending Economic and Social Conundrum. Journal of Politics and Law Vol. 4, No. 2. (September 2011):196, http://ccsenet.org/journal/index.php/jpl/article/viewFile/12011/8435. (accessed on January 11,2015). Waziri K.M,“The Legal Regime Of Patents And Designs Law And its Effects On National Development,”:5, http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1875725 (accessed March 23, 2015). Wechkin John M., “Drug Price Regulation And Compulsory Licensing for Pharmaceutical Patents: The New Zealand Connection,”(1995):239, digital.law.washington.edu/dspace-law/...1/.../5PacRimLPolyJ237.pdf? (accessed March 28, 2015). Who global malaria programme World malaria report 2012:xiii. file:///C:/Users/Musa/Downloads/who%20and%20malaria.pdf (accessed January 8, 2015). Wipo Intellectual Property Handbook (2008):17, www.wipo.int/edocs/pubdocs/en/intproperty/489/wipo_pub_489.pdf (accessed March 23, 2015). Winifred Ogbebo and Victor Okeke, “States Yet To Set Up Drug Distribution Centres – Minister,” (June 24, 2014, http://leadership.ng/news/375732/states-yet-set-drug-distribution-centres-minister (accessed March 12, 2015). “WTO and the Trips Agreement,” http://www.who.int/medicines/areas/policy/wto_trips/en/ (accessed February 28, 2015). Yusufu Hashim Ubale, “Challenges in Addressing the Problem of Illicit Production, Distribution and Trafficking Of Fraudulent Medicines – Challenges from a Regulatory Agency,” (14 – 15th february,2013):14, http://www.unodc.org/documents/organizedcrime/FM/Yusufu_Ubale.pdf (accessed January 20, 2015). Zimmerman Eilene, “TruTags Stymie Drug Counterfeiters An innovative micro-tag made nano-porous silica makes it nearly impossible for counterfeiters to duplicate when placed on the surface of pharmaceutical pills.,” http://www.inc.com/articles/201106/trutags-stymie-drug-counterfeiters.html (accessed February 20, 2015). Zaggi Hassan,“The Need To Support Death Sentence For Fake Drug Dealers,” www.gamji.com/article8000/NEWS8815.htm (Accessed May 23, 2015). BOOKS. Cornish W. and D.Llewelyn, “Intellectual Property:Patents,Copyright,Trade marks and Allied Rights, “ 6th Edition (London:Sweet and Maxwell,2007). Devi K. Uma, G. Indira Priya Darsini and V. Sowbhagya Rani, The Law of Intellectual Property Rights Various Dimensions (New Delhi: Regal Publications). Helfer Laurence R. and Graeme W. Austin, Human Rights and Intellectual Property Mapping the Global Interface(United States of America: Cambridge University Press). National Agency for Foods and Drugs Administration and Control Information Brochure (Ilupeju:Integrated Press Ltd),2-3. Shyllon Folarin, Intellectual Property Law in Nigeria, (Munich:Max Planck Institute for Intellectual Property, Competition and Tax Law, 2003). Torreman Paul, “Intellectual Property Law,” 4th Edition (USA:Oxford University Press, 2005). Yaqin Anwarul, Legal Research and Writing, (Malaysia: International Islamic University Dolphin Press,2007).

The role compulsory licensing in combatting counterfeit drugs in Nigeria

Similar Items